Elicio Therapeutics (ELTX) Non-Current Debt (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Non-Current Debt for 4 consecutive years, with $9.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt rose 2.12% year-over-year to $9.5 million; the trailing twelve-month figure through Jun 2026 stood at $9.5 million (up 2.12% YoY), and the FY2025 full-year result was $9.4 million, down 53.04% from the prior year.
• Non-Current Debt grew to $9.5 million in Q2 2026 per ELTX's latest filing, from $9.5 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $20.0 million in Q4 2024 and bottomed at $9.3 million in Q2 2025.
• Historically, Non-Current Debt has averaged $11.3 million across 3 years, with a median of $9.5 million in 2026.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt tumbled 53.04% in 2025, then increased 2.12% in 2026.
• Over 3 years, Non-Current Debt stood at $20.0 million in 2024, then sank by 53.04% to $9.4 million in 2025, then gained by 1.36% to $9.5 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $9.5 million, $9.5 million, and $9.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.